Search

Your search keyword '"D, Pascual Salcedo"' showing total 148 results

Search Constraints

Start Over You searched for: Author "D, Pascual Salcedo" Remove constraint Author: "D, Pascual Salcedo" Language english Remove constraint Language: english
148 results on '"D, Pascual Salcedo"'

Search Results

2. Influence of rheumatoid factor levels and TNF inhibitor structure on secondary nonresponse in rheumatoid arthritis patients.

3. Influence of rheumatoid factor on serum drug levels of TNF inhibitors with different structures in rheumatoid arthritis.

4. Early monitoring of anti-infliximab antibodies by drug-tolerant assay predicts later immunogenicity and drug survival in rheumatic diseases.

5. Translation and cross-cultural adaptation of the mSQUASH into Spanish.

6. Coping with rheumatic stressors (CORS) questionnaire: Spanish translation and cross-cultural adaptation.

7. Low Serum BAFF Concentration Is Associated with Response to TNF Inhibitors in Seropositive Patients with Rheumatoid Arthritis.

8. Early monitoring of infliximab serum trough levels predicts long-term therapy failure in patients with axial spondyloarthritis.

9. Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses.

10. Methotrexate Reduces the Probability of Discontinuation of TNF Inhibitors in Seropositive Patients With Rheumatoid Arthritis. A Real-World Data Analysis.

11. Remission Induced by TNF Inhibitors Plus Methotrexate is Associated With Changes in Peripheral Naïve B Cells in Patients With Rheumatoid Arthritis.

12. BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors.

13. Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar.

14. Blood Lymphocyte Subsets for Early Identification of Non-Remission to TNF Inhibitors in Rheumatoid Arthritis.

15. Reduction in antidrug antibody levels after switching to rituximab in patients with rheumatoid arthritis with prior infliximab or adalimumab secondary failure.

16. Improved RA classification among early arthritis patients with the concordant presence of three RA autoantibodies: analysis in two early arthritis clinics.

17. Low serum calprotectin levels correlate with the presence of biological drugs after the first year of treatment in patients with rheumatoid arthritis.

18. The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors.

19. Specific Association of HLA-DRB1*03 With Anti-Carbamylated Protein Antibodies in Patients With Rheumatoid Arthritis.

20. Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept.

21. Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis.

22. Differential blood cellular profile in patients with moderate-to-severe psoriasis treated with classical systemic therapies: a step forward in personalized medicine.

23. Golimumab Tapering Strategy Based on Serum Drug Levels in Patients With Spondyloarthritis.

24. Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis.

25. IgA anti-β2 glycoprotein I antibodies: Experience from a large center.

26. Optimal concentration range of golimumab in patients with axial spondyloarthritis.

27. Impact of immunogenicity on response to anti-TNF therapy in moderate-to-severe plaque psoriasis: results of the PREDIR study.

28. Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases.

29. Value of Measuring Anti-Carbamylated Protein Antibodies for Classification on Early Arthritis Patients.

30. Rationale for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Diseases.

31. Current Practices for Therapeutic Drug Monitoring of Biopharmaceuticals in Pediatrics.

32. Infusion reactions during infliximab treatment are not associated with IgE anti-infliximab antibodies.

33. Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study.

34. Monitoring serum etanercept levels in juvenile idiopathic arthritis: a pilot study.

35. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars.

36. Influence of elevated-CRP level-related polymorphisms in non-rheumatic Caucasians on the risk of subclinical atherosclerosis and cardiovascular disease in rheumatoid arthritis.

37. Comparing a tapering strategy to the standard dosing regimen of TNF inhibitors in rheumatoid arthritis patients with low disease activity.

38. Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis.

39. Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations: A Cohort Study in Clinical Practice Conditions.

40. Comparison study of two commercially available methods for the determination of golimumab and anti-golimumab antibody levels in patients with rheumatic diseases.

41. Comparing Tapering Strategy to Standard Dosing Regimen of Tumor Necrosis Factor Inhibitors in Patients with Spondyloarthritis in Low Disease Activity.

42. Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study.

43. Antiphospholipid antibodies correlate with stroke severity and outcome in patients with antiphospholipid syndrome.

44. Lack of association between JAK3 gene polymorphisms and cardiovascular disease in Spanish patients with rheumatoid arthritis.

45. Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practice.

46. Anti-adalimumab antibodies in paediatric rheumatology patients: a pilot experience.

47. Osteoprotegerin CGA haplotype protection against cerebrovascular complications in anti-CCP negative patients with rheumatoid arthritis.

48. Interferon regulatory factor 5 genetic variants are associated with cardiovascular disease in patients with rheumatoid arthritis.

49. Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis.

50. Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome.

Catalog

Books, media, physical & digital resources